Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)

NCT06467981 | Completed

• 1 other identifier: 2024PI105
• Study Type: observational
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

The recent clinical authorization of amyloid Positon Emission Tomography (PET) in France represents a crucial step for the nuclear medicine community involved in the diagnosis of Alzheimer's disease (AD).

Conditions

Alzheimer Disease

Outcome Measures

Primary Outcomes (1)

• Evaluate the indications for Amyloid PET in 7 centers in France to assess the relevance of the examination

  Correlation between the request and the recommendations

  1 day

Secondary Outcomes (1)

• Evaluate the frequency of positive examinations for the diagnosis of AD

  1 day

Interventions

Retrospective study OTHER

The data from the PET request form will be collected in each center for this population of patients who have had an amyloid PET scan with flutemetamol and the results of the PET examination reports will also be provided, all data will be made anonymous.

Also known as: Filled request form of PET for each patient

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

All patients who had a flutemetamol amyloid PET scan with a PET request form including the indications for the examination and who received the information letter on the objectives of the research and who did not object to the use of their data.

You may qualify if:

• Patients aged = or \> 18 years
• Patients who have had an amyloid PET scan with a PET request form including the indications for the examination
• Patient informed via a newsletter and non-opposition to the use of their data for research purposes (research objectives clearly explained in the letters)

You may not qualify if:

• Patient opposition to the use of their data for this research

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Nuclear medicine department

Vandœuvre-lès-Nancy, 54511, France

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Retrospective Studies

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Case-Control Studies; Epidemiologic Studies; Epidemiologic Study Characteristics; Epidemiologic Methods; Investigative Techniques; Cohort Studies; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Investigator coordinator

Study Record Dates

• First Submitted: June 11, 2024
• First Posted: June 21, 2024
• Study Start: November 1, 2024
• Primary Completion: December 30, 2024
• Study Completion: February 15, 2025
• Last Updated: June 5, 2025

Record last verified: 2024-09

Locations

FR (1)